Literature DB >> 7127334

Etoposide--chemistry, preclinical and clinical pharmacology.

W Achterrath, N Niederle, R Raettig, P Hilgard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7127334     DOI： 10.1016/s0305-7372(82)80072-8

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  6 in total

1.  High dose etoposide does not cause peripheral neuropathy.

Authors:  T J Littlewood; D P Bentley; I N McQueen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.

Authors:  S Naito; T Ueda; S Kotoh; J Kumazawa; K Itoh; K Sagiyama; T Omoto; S Andoh; Y Hasegawa; Y Fujisawa
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 3.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

4.  Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line.

Authors:  P J Hepburn; R T Oliver; P A Riley; B T Hill; J R Masters
Journal:  Urol Res       Date:  1985

5.  EPIC: an effective low toxicity regimen for relapsing lymphoma.

Authors:  T Hickish; A Roldan; D Cunningham; J Mansi; S Ashley; V Nicolson; M E Gore; D Catovsky; I E Smith
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

6.  Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.

Authors:  T C Kok; A Van der Gaast; J Dees; W M Eykenboom; H Van Overhagen; G Stoter; H W Tilanus; T A Splinter
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.